QUILT 3032: Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle- invasive bladder cancer (NMIBC) Jun 15, 2022 | Bladder Cancer
Phase 2 QUILT 88 trial of DAMP inducers combined with IL15 superagonist, N-803 and anti PDL1-t-haNK cell therapy more than doubles historical overall survival with 3rd to 6th line advanced Pancreatic Cancer Jun 15, 2022 | Pancreatic Cancer
CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma May 2, 2022 | Uncategorized
QUILT-88: NANT Pancreatic Cancer Vaccine in 3rd, 4th, & 5th Line Advanced Disease Mar 25, 2022 | Pancreatic Cancer
Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) Mar 16, 2022 | Bladder Cancer